Boston, MA -- (SBWIRE) -- 08/30/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (GT Advanced Technologies Inc(NASDAQ:GTAT), Sunedison Inc (NYSE:SUNE), Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR)
GT Advanced Technologies Inc(NASDAQ:GTAT) shares gained 2.51% to $6.54. Research analysts at Gilford Securities boosted their target price on shares of GTAT from $6.40 to $10.00 in a report released on August 22. The firm currently has a “buy” rating on the stock.
Additionally, the company on August 5 reported results for the second quarter of fiscal year 2013, which ended June 29, 2013. Revenue for the second quarter came in at $168.3 million. Non-GAAP net income was $18.1 million in the second quarter, compared to a non-GAAP net loss of $8.9 million in the first quarter and non-GAAP net income of $19.3 million for the second quarter of calendar 2012.
How Should Investors Trade GTAT After The Recent Volatility? Get Free Report Here
Sunedison Inc (NYSE:SUNE) shares gained 1.62% to $7.52. The company on August 22 said it would spin off its semiconductor business in an initial public offering and use the proceeds to fund its solar business. The company said it plans to sell a minority stake in the newly formed SunEdison Semiconductor to the public in the offering, scheduled for early 2014.
The company ended the second quarter with a project pipeline of 2.9 GW, up 218 megawatt from the first quarter.
How Should Investors Trade SUNE After The Recent Volatility? Get Free Report Here
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) shares gained 0.73% to $6.87. The company, on August 28, announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course. As of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML, and 17 patients in the treatment-naive elderly AML not suitable for induction chemotherapy cohort). The primary endpoint is overall remission rate (Complete Remission or CR; Complete Remission with Incomplete hematologic recovery or CRi/CRp).
Is ASTX A Good Buy After The Recent Price Movement? Find Out Here
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) shares jumped 2.33% to $5.28. The company on August 22 announced the publication of the findings from the PRISM patient registry in PLOS ONE, an international, peer-reviewed, open-access medical journal. PRISM was the largest registry ever conducted to further understand prevalence and impact of pseudobulbar affect (PBA) in the United States.
Additionally, the company on August 12 said it reached an exclusive agreement to promote pharmaceutical giant Merck & Co.'s type-2 diabetes drug Januvia in long-term care institutional settings in the U.S. Under the accord, Avanir institutional sales force will begin promoting the sitagliptin family of products to health-care practitioners in the long-term care institutional setting in October.
Is AVNR A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)